Intravenous Voriconazole in Patients With Renal Compromise

The purpose of this study is to determine whether patients with compromised renal function
(CrCl < 50mL/min) receiving intravenous voriconazole experienced any adverse effects related
to serum chemistries or other imaging studies of the kidney due to the potential accumulation
of the vehicle cyclodextran. t has been previously shown by a large multi-centered,
prospective, randomized study that voriconazole is superior to the then gold standard
amphotericin B in the treatment of patients with invasive aspergillosis - a disease with
significant morbidity and mortality. In patients with these infections who have severe renal
insufficiency may be denied the best therapy due to the accumulation of a diluent with
unknown clinical consequences. Qualifying and or quantifying these consequences are important
to these patients so that potentially life-threatening therapy should not be unduly denied.

Inclusion Criteria:

- Patients > 18 years old receiving voriconazole with a serum creatinine of > 2mg/dl (a
proxy marker for Creatinine clearance < 50ml/min). Control group in this study will have
serum creatinine < 1.5mg/dl. Solid organ transplant patient. Patient that received at least
2 doses of voriconazole.

Exclusion Criteria: